telavancin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4116 372151-71-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • telavancin
  • arbelic
  • telavancin hydrochloride
  • vibativ
  • telavancin HCl
an anti-infective agent
  • Molecular weight: 1755.65
  • Formula: C80H106Cl2N11O27P
  • CLOGP: 1.87
  • LIPINSKI: 3
  • HAC: 38
  • HDO: 23
  • TPSA: 598.09
  • ALOGS: -5.08
  • ROTB: 30

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.11 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.07 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 11, 2009 FDA THERAVANCE BIOPHARMA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XA03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Glycopeptide antibacterials
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
FDA EXT N0000191280 Lipoglycopeptides
FDA EPC N0000191281 Lipoglycopeptide Antibacterial
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bacterial pneumonia indication 53084003 DOID:874
Pneumonia due to Staphylococcus aureus indication 441658007
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection indication
Complicated Skin and Skin Structure Infection indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Torsades de pointes contraindication 31722008
Hypertensive disorder contraindication 38341003 DOID:10763
Chronic heart failure contraindication 48447003
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Prolonged QT interval contraindication 111975006
Decompensated cardiac failure contraindication 195111005
Impaired renal function disorder contraindication 197663003
Pregnancy, function contraindication 289908002
Pseudomembranous enterocolitis contraindication 397683000
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.06 acidic
pKa2 2.59 acidic
pKa3 6.27 acidic
pKa4 7.41 acidic
pKa5 7.98 acidic
pKa6 10.14 acidic
pKa7 10.72 acidic
pKa8 11.49 acidic
pKa9 12.61 acidic
pKa10 12.69 acidic
pKa11 13.01 acidic
pKa12 13.37 acidic
pKa13 13.47 acidic
pKa14 12.0 Basic
pKa15 9.53 Basic
pKa16 8.33 Basic
pKa17 5.6 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4029465 VUID
N0000180310 NUI
D06057 KEGG_DRUG
560130-42-9 SECONDARY_CAS_RN
4029465 VANDF
4029466 VANDF
C1453642 UMLSCUI
CHEBI:71229 CHEBI
CHEMBL507870 ChEMBL_ID
CHEMBL3301680 ChEMBL_ID
6918702 PUBCHEM_CID
C487637 MESH_SUPPLEMENTAL_RECORD_UI
8504 INN_ID
DB06402 DRUGBANK_ID
XK134822Z0 UNII
10925 IUPHAR_LIGAND_ID
473837 RXNORM
167756 MMSL
26725 MMSL
30522 MMSL
d07483 MMSL
013290 NDDF
013291 NDDF
443552009 SNOMEDCT_US
443553004 SNOMEDCT_US
768493001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vibativ HUMAN PRESCRIPTION DRUG LABEL 1 52118-001 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 33 sections
Vibativ HUMAN PRESCRIPTION DRUG LABEL 1 52118-002 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 33 sections
VIBATIV HUMAN PRESCRIPTION DRUG LABEL 1 66220-315 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 mg INTRAVENOUS NDA 30 sections